#1Improving Patient Outcomes In Critical Care Settings Developing rapid, near-patient products for treatment guidance and monitoring wyp DIAGNOSTICS#2Disclaimer Forward-looking Statements This presentation contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Litigation Reform Act. Forward-looking statements in this presentation include, without limitation, the expected nature and timing of the Company's planned FDA submission and related plans for clinical study expansion, whether the Company's cash position will be sufficient to fund operations needed to achieve regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such regulatory approval will actually occur. Forward-looking statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "suggest", "will," and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. This presentation speaks as of the date indicated. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company's expectations of results or any future change in events. bluejay DIAGNOSTICS Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 2#3Bluejay Diagnostics: Optimizing Turnaround Times to Improve Patient Outcomes $ DOC ●●● Novel Proprietary Platform ●● Symphony™ Product Lead Candidate: IL-6 Assay Market Opportunity Commercial Strategy $Capital Efficient Model bluejay DIAGNOSTICS Uses whole blood (no pre-processing) Results in ~20 minutes Completed initial clinical studies for measuring IL-6 in critical care settings Conducting additional studies to support planned FDA submission TM Symphony™ Product Pipeline addresses multi-billion-dollar market Near-patient testing (NPT) for monitoring of disease progression Sales model initially targets clinical sites and commercial partnerships Large, well-respected clinical sites are built-in commercial customers $6.8 M in cash as of March 31, 2023 The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 3#4The SymphonyTM Technology Platform: Analyzer and Assay Cartridge Developing tests for clinically relevant biomarkers in critical care settings ●●● Symphony Symphony bluejay Symphony Runs up to 6 tests simultaneously Fluorescence-based immunoanalyzer bluejay The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA DIAGNOSTICS Symphony Content 31266 eng FOR NAONAL ON bluejay Sympheny SymphonyTM Cartridges No additional chemicals No pre-processing of the sample Advanced microfluidics nanotechnology ELISA = Enzyme-Linked Immunosorbent Assay Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 4#5$1.2 Billion Total Addressable IL-6 Testing Market in Acute Care Settings (US Annual) Potential testing revenue from IL-6 testing in long-term acute care facilities (LTACs), emergency departments (EDs), and intensive care units (ICUS) DESCRIPTION Number of patients Percentage of patients with clinician ordered IL-6 tests³ Average number of IL-6 tests ordered for each patient³ Estimated number of IL-6 tests performed Cost per test to the lab4 Total Addressable Market for IL-6 testing Testing increase expected with Bluejay's Symphony IL-6 test³ Total Addressable Market with Bluejay's Symphony IL-6 test ●●● 00 DIAGNOSTICS LTACs 400,000¹ 27.5% 3.4 0.37 M $150 $56.1 M 26.4% $70.9 M ICUS 3,100,000² 26.5% 3.7 3.0 M $150 $453.5 M 57.7% $714.9 M Bluejay's Symphony has potential to expand use of IL-6 testing in acute care settings: increase testing volumes by 54.6% 1 Harmony Healthcare: https://harmony.solutions/understanding-care-long-term-acute-care-hospitals-101/ 2National Center for Health Statistics, National Hospital Ambulatory Medical Care Survey, 2020 3Frost & Sullivan primary research 4Bluejay pricing expectations per IL-6 test under DRG coding The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA raise TAM to $1.8 B EDS 5,345,000² 23.5% 3.5 4.4 M $150 $663.2 M 54.9% $1,027.3 M Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 5#6Sepsis: Time is the Enemy Earlier detection is needed to prevent patients from progressing to septic shock Sepsis Challenging to identify at risk patients in early stage since symptoms mimic many conditions HIGHEST CHANCE FOR FULL RECOVERY AT THIS STAGE ●●● O DIAGNOSTICS IL-6 biomarker levels elevate early Sepsis is a leading cause of death in the U.S. Sepsis is one of most costly conditions to treat: Septic Shock Patients rapidly deteriorate at this most dangerous stage, with >40% mortality Sources: Sepsis Alliance and The Lancet Respiratory Medicine, 2017 Vol. 5 (6) p.524-534 ~80% OF DEATHS COULD BE PREVENTED WITH RAPID DIAGNOSIS IL-6 measurement offers quick snapshot of disease progression More than 1.7m people/year get sepsis Cost to treat is more than $62B/year ~350k people die/year 3rd leading cause of death #1 cost of hospitalization in U.S. Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 6#7Symphony™M IL-6 Test: Rapid Results in Critical Care Settings Quantitative determination of IL-6 by fluorescence enzyme immunoassay from whole blood specimens ●●● DIAGNOSTICS Measuring IL-6 could help medical professionals make earlier and actionable treatment decisions. Rapid turnaround time crucial as 'time is the enemy' in critical care settings. Interleukin-6 (IL-6) is an Early Responder Biomarker During Trauma or Infection. Important in: Acute Respiratory Distress Syndrome Multi-organ Failure Cardiovascular Diseases Autoimmune Disorders The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Sepsis And Covid-19 Related Sepsis Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 7#8SymphonyTM Transforms Care with Rapid, Near-Patient Testing Enables Physicians to make actionable treatment decisions earlier for patient stratification Current Testing Methods: Time is the Enemy Significantly longer turnaround times to get results back to patients minimizes utility for critical care Require highly trained technicians to operate Large equipment located in central lab settings ● ● ● Symphony's Differentiated Features: Faster results to actionable decisions Quantitative, lab quality results System utilizes whole blood (no pre-processing required) Mobile, near-patient system ● ● ● ● bluejay DIAGNOSTICS Physician orders test Patient (critical care setting) Physician orders test 4 Patient (ICU/long-term care setting) The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Blood drawn from patient Turnaround time: several hours Physician uses test results to guide treatment Blood drawn from patient Turnaround time: ~20 minutes Blood sample transported to testing site Physician uses test results to guide treatment Lab results reported back to physician Sample processed near patient Symphony - bluejay Sympheny Symphony™ System Stary Sample processed at central testing site Central Testing Lab Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 8#9Symphony™M IL-6 Potential Clinical Advantages v. Current Standard Tests Metric Area Under Receiver Operator Characteristic Curve (AUC) Youden Index Cutoff Sensitivity Specificity NPV 00 Interleukin-6 (IL-6) 0.801 DIAGNOSTICS 1.52 35 pg/mL 0.89 (0.65, 0.99) 0.64 (0.55, 0.72) 0.98 (0.92, 1.00) C-Reactive Protein (CRP) 0.578 1.35 113.95 mg/mL 0.44 (0.22, 0.69) 0.91 (0.84, 0.95) 0.92 (0.86, 0.96) Lactate 0.680 1.29 1.75 mmol/L 0.56 (0.31, 0.78) 0.74 (0.61, 0.84) 0.85 (0.72, 0.93) Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Sensitivity 1.0 0.8- 0.6- 0.4 0.2- 0.0- T 1.0 ROC Curves of Biomarker Prediction of IMV 0.8 0.6 IL-6 (AUC = 0.801) CRP (AUC = 0.578) Lactate (AUC = 0.680) 0.4 Specificity An analysis of the Bluejay's clinical study assessing the ability of Symphony IL-6 at time of hospital admission to predict patients at risk for invasive mechanical ventilation (IMV) during their hospitalization demonstrated favorable clinical performance with a sensitivity of 89%, specificity of 64%, and negative predictive value of 98%, highlighting the potential higher clinical utility of IL-6 compared to these other standard biomarkers to identify patients at future risk of IMV. 0.2 0.0 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 9#10SymphonyTM System Commercial Advantages¹ v. Other Clinical Analyzer Systems Advantages Near Patient Test System Size Sample Type Separate Sample Processing Step Total Turnaround Time Requires Dedicated Personnel* System/Infrastructure Cost NPV2 for IL-6 Assay *(phlebotomist/MedTech) bluejay DIAGNOSTICS Bluejay Symphony™ Near patient Desktop Whole blood No ~20 minutes No $ 98% Beckman Coulter Central Lab Very Large Serum/plasma Yes 4-48hr³ Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Yes $$$ 78.6%4 Siemens Central Lab Very Large Serum/plasma Yes 4-48hr³ Yes $$$ 86%4 Roche Central lab Very Large Serum/plasma Yes 4-48hr³ Yes $$$ 92.9%4 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 10#11Symphony IL-6 Regulatory Timeline ●●● bluejay DIAGNOSTICS Q4 '21 Began initial clinical trials Q2 '22 FDA feedback; including de novo designation Q1 '22 Filed FDA pre-submission Q4 '22 Filed pre-submission supplement with FDA Q3 '22 Completed initial clinical trials Q1 '23 FDA feedback; study expansion required Q4 '22 Expanded trials to support de novo submission H1 24 Planned FDA submission Q2 '23 Modify trial inclusion to obtain more patient data 2025 Planned commercialization H2 ¹24 Planned FDA submission response Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 11#12Launch Plan Starts by Converting Bluejay Clinical Trial Sites to Commercial Sites Existing multi-location healthcare testing sites are built-in initial commercial customers Stage 1 Clinical Study testing sites ●●● ●● DIAGNOSTICS Stage 2 Convert testing sites to commercial sites Commercial Strategy Leveraging internal champions to drive adoption Stage 3 Expand to additional sites within same hospital system Stage 4 Broaden commercialization to wider customer base beyond testing sites Consumables Model Cartridges provide recurring revenue and favorable margins June 2023 12#13SymphonyTM Product Pipeline ●●● Products TM Symphony ™M IL-6 Test patient acuity for sepsis triage/monitoring Symphony TM hsTNT/I patient acuity with chest pain TM Symphony ™M NT-proBNP patient acuity with chest pain DIAGNOSTICS Research Other well-validated critical care biomarkers Development New Tests Will Follow the IL-6 Development Pathway. Plan to expand testing menu to include: The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Clinical Testing Regulatory Tests with potential clinical and cost-saving benefits gained from faster turnaround times Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 13#14Financial Highlights Financial Info (March 31, 2023) Cash* Est. Cash Runway Clean Balance Sheet BJDX (NASDAQ) (June 1, 2023) Market Cap Average Daily Trading Volume (30 day) Shares Outstanding DIAGNOSTICS $6.8 M < 12 months No outstanding warrants or debt $4.6M 313K shares 20.5M The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Symphony Symphony L Symphony Symphony f yo Erbacity Sympheny 000 Kelanta Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 14#15Management & Advisors: Leadership, Diagnostic & Product Launch Expertise Indranil "Neil" Dey CEO and Co-founder Involved in introducing Her2neu test for Herceptin Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK TM bluejay DIAGNOSTICS IMPATH The Cancer Information Company Kenneth Fisher Chief Financial Officer Responsible for finance, investor relations, accounting and administrative operations CPA; BA, Business Administration, Isenberg School of Management, University of Massachusetts at Amherst East Boston Savings Bank Jason Cook Chief Technology Officer Responsible for product development and manufacturing operations 15+ years in POC/ diagnostics product development Ph.D. in Biomedical Engineering, University of Texas at Austin D TEXAS The University of Texas at Austin Mark Feinberg Chief Medical Advisor Responsible for clinical development programs and strategic medical leadership Associate Professor, Harvard Medical School/Cardiovascular, Brigham & Women's; Medical College of Pennsylvania Brigham and Women's Hospital Founding Member, Mass General Brigham Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 15#16Board of Directors Douglas C. Wurth, Chairman Indranil "Neil" Dey, CEO Svetlana Dey Donald R. Chase Fred S. Zeidman Gary Gemignani J.P. Morgan ●●● ●● DIAGNOSTICS Skadden 20-year career at J.P. Morgan Chase (CEO of the International Private Bank & Alternative Investments, Asset Management) B.A Notre Dame University; J.D. University of Virginia School of Law; practiced law at Skadden, Arps, Meagher and Flom Involved in introducing Her2neu test for Herceptin and introduction of Erbitux Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary; MBA (Fulbright Scholar) from Cambridge University, UK Co-founder of Bluejay; President & CEO of LMBRI LLC; 15 years+ of management experience in healthcare industry Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years in executive roles at well-known community banks in New England B.S. Accounting, Western New England University 50+ years of corporate advisory experience; Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis; Masters in Business Administration from New York University Senior executive with experience in life sciences, public companies, accounting/finance Prior experience with Acacia Pharma, Biodel, Prudential Financial, Gentium, Novartis, Wyeth and Arthur Andersen IMPATH" The Con Company Imbri merchants BANCSHARES INC westbank UNITED STATES MEMORIAL MUSEUM ARTHUR ANDERSEN Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 16#17Symphony Contents 21204 HAP Cyb 3. Po coming FOR INVESTIGATIONAL USE bluejay Sympheny Symphony Symphony bluejay Improving Patient Outcomes In Critical Care Settings Developing rapid, near-patient products for treatment guidance and monitoring wyp bluejay DIAGNOSTICS#18DIAGNOSTICS Contact Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Toll-free: 844.327.7078 Main: 978.631.4884 [email protected]